OR WAIT 15 SECS
Univercells will integrate its single-use bioprocess with the Takeda vaccines production platform to allow local production.
Belgian-based bioprocess developer Univercells partnered with Takeda Pharmaceutical Company Limited through its strategic venture arm, Takeda Ventures, to tailor Univercells’ continuous integrated manufacturing methods and integrate them into the Takeda vaccines production platform, Univercells announced on Oct. 22, 2015. Univercells uses process intensification and single-use solutions to reduce infrastructure investment and allow local, flexible production.
“Equal access to health around the globe is critical and we believe this comes through decentralized production, which is the biggest challenge in this new era of biomanufacturing," said Jose Castillo, CTO of Univercells, in a press release.
“Takeda is committed to making its vaccines available to people in need, wherever they may live. Reducing production costs while maintaining the highest levels of quality is an important part of our access strategy, and manufacturing science plays a critical role,” said Dr. Rajeev Venkayya, president of Takeda’s Vaccine business unit, in the release.